Keywords: Geron, Angiochem, License, Peptide technology, GRN1005, Brain cancer

Geron expands clinical oncology pipeline in deal with Angiochem for brain cancer drugs

Article | 07 December 2010

Print This

California, USA-based Geron Corp (Nasdaq: GERN) has entered into an agreement with privately held Canadian firm Angiochem for a worldwide ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in